Stage III Renal Cell Cancer AJCC v8 Clinical Trials
17 studies are recruiting for stage iii renal cell cancer ajcc v8 in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
By city
Studies now recruiting
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has …
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Kingman Regional Medical Center, Kingman, Arizona
- Locations
- 328 in total
- Run by
- NRG Oncology
-
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Yale University Cancer Center LAO, New Haven, Connecticut
- Run by
- National Cancer Institute (NCI)
-
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).…
- Stage
- Phase 2
- Ages
- 12 and older
- Site
- Emory University Hospital Midtown, Atlanta, Georgia
- Locations
- 13 in total
- Run by
- National Cancer Institute (NCI)
-
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…
- Stage
- Phase 1
- Ages
- 16 and older
- Site
- Mayo Clinic in Florida, Jacksonville, Florida
- Run by
- Mayo Clinic
-
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- City of Hope National Medical Center, Duarte, California
- Locations
- 6 in total
- Run by
- Vanderbilt-Ingram Cancer Center
-
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell kidney (renal cell) cancer that has not spread to other parts of the body (localized). Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune sys…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- City of Hope Medical Center, Duarte, California
- Run by
- City of Hope Medical Center
-
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
This phase I/II trial tests the safety and effectiveness of inulin gel in combination with ipilimumab and nivolumab in treating patients with kidney cell cancer (renal cell carcinoma [RCC]) that has spread from where it first started (primary site) to other places in the body (metastatic) or has sp…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
- Run by
- University of Michigan Rogel Cancer Center
-
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumor…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of California, San Francisco, San Francisco, California
- Run by
- Rahul Aggarwal
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced)…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- M D Anderson Cancer Center, Houston, Texas
- Run by
- M.D. Anderson Cancer Center
-
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivo…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope Medical Center, Duarte, California
- Locations
- 2 in total
- Run by
- City of Hope Medical Center
-
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced…
- Stage
- Phase 4
- Ages
- 18 and older
- Site
- OHSU Knight Cancer Institute, Portland, Oregon
- Run by
- OHSU Knight Cancer Institute
-
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas
- Locations
- 41 in total
- Run by
- SWOG Cancer Research Network
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Mayo Clinic in Florida, Jacksonville, Florida
- Run by
- Mayo Clinic
-
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibitor. Immunotherapy wi…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- City of Hope Medical Center, Duarte, California
- Locations
- 2 in total
- Run by
- City of Hope Medical Center
-
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
This phase II trial tests adding VSV-IFNβ-NIS to standard of care ipilimumab and nivolumab for the treatment of clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it fi…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Mayo Clinic in Rochester, Rochester, Minnesota
- Run by
- Mayo Clinic
-
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Mayo Clinic in Arizona, Phoenix, Arizona
- Locations
- 3 in total
- Run by
- Mayo Clinic
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope Medical Center, Duarte, California
- Run by
- Osel, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.